Background: There have been few studies on risk factors and treatment outcomes of isoniazid (H)-resistant tuberculosis (TB), and optimal treatment regimens are debated. Aim: To identify risk factors for H-resistant TB, de-scribe treatment regimens and compare these to na-tional guidelines and describe short-term outcome
The World Health Organization (WHO) defines multidrug-resistant tuberculosis (MDR-TB) as resistance ...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
IntroductionIsoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common form...
BACKGROUND There have been few studies on risk factors and treatment outcomes of isoniazid (H)-re...
Abstract: Background and objectives: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB...
Background: Drug resistance tuberculosis remains major public health problem worldwide. In India, th...
Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resi...
Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to IN...
INTRODUCTION:Isoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common for...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure...
Multidrug-resistant tuberculosis (MDR-TB) is a severe and feared problem, that is difficult to contr...
Background: Active tuberculosis (TB) in patients with latent tuberculosis infection (LTBI) was assoc...
BACKGROUND: Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
BACKGROUND: Approximately 7% of all reported tuberculosis (TB) cases each year are recurrent, occurr...
Objective: 1) To identify socio-demographic and treatment related risk factors predictive of default...
The World Health Organization (WHO) defines multidrug-resistant tuberculosis (MDR-TB) as resistance ...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
IntroductionIsoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common form...
BACKGROUND There have been few studies on risk factors and treatment outcomes of isoniazid (H)-re...
Abstract: Background and objectives: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB...
Background: Drug resistance tuberculosis remains major public health problem worldwide. In India, th...
Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resi...
Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to IN...
INTRODUCTION:Isoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common for...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure...
Multidrug-resistant tuberculosis (MDR-TB) is a severe and feared problem, that is difficult to contr...
Background: Active tuberculosis (TB) in patients with latent tuberculosis infection (LTBI) was assoc...
BACKGROUND: Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
BACKGROUND: Approximately 7% of all reported tuberculosis (TB) cases each year are recurrent, occurr...
Objective: 1) To identify socio-demographic and treatment related risk factors predictive of default...
The World Health Organization (WHO) defines multidrug-resistant tuberculosis (MDR-TB) as resistance ...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
IntroductionIsoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common form...